Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progression.

ABSTRACT:

SUBMITTER: Foldi J 

PROVIDER: S-EPMC10316092 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature